These results suggest that β-cryptoxanthin, by regulating ZNF451 expression, not only inhibits the malignant behavior of cisplatin-resistant osteosarcoma cells but also increases their sensitivity to cisplatin, highlighting its potential application in osteosarcoma treatment. Here, ZNF451 is linked to osteosarcoma.